Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Receivables - Accured (2023 - 2025)

Metagenomi (MGX) has disclosed Receivables - Accured for 3 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Receivables - Accured fell 25.0% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 25.0% year-over-year, with the annual reading at $1.2 million for FY2025, 25.0% down from the prior year.
  • Receivables - Accured for Q4 2025 was $1.2 million at Metagenomi, down from $1.3 million in the prior quarter.
  • The five-year high for Receivables - Accured was $1.6 million in Q3 2024, with the low at $1.0 million in Q4 2023.
  • Average Receivables - Accured over 3 years is $1.4 million, with a median of $1.4 million recorded in 2024.
  • The sharpest move saw Receivables - Accured surged 60.0% in 2024, then dropped 25.0% in 2025.
  • Over 3 years, Receivables - Accured stood at $1.0 million in 2023, then skyrocketed by 60.0% to $1.6 million in 2024, then decreased by 25.0% to $1.2 million in 2025.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $1.2 million, $1.3 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.